← Back to Search

Lacosamide for Neonatal Seizures (LENS Trial)

Phase 2
Recruiting
Research Sponsored by UCB Biopharma SRL
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participant weighs at least 2.3 kg at the time of enrollment Informed consent
Participants must have received either phenobarbital (PB), levetiracetam (LEV), or midazolam (MDZ) (in any combination) before entering the study
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during 2-hour evaluation starting 1 hour after initial treatment (up to 2 hours)
Awards & highlights

LENS Trial Summary

This trial will compare the efficacy of lacosamide to an active comparator chosen based on standard of care in reducing seizure burden in neonates with uncontrolled seizures.

Who is the study for?
This trial is for newborns between 34 and <46 weeks of corrected gestational age, weighing at least 2.3 kg, with uncontrolled seizures despite previous treatment with certain anti-epileptic drugs. Newborns must not have seizure causes that are correctable or related to prenatal drug issues.Check my eligibility
What is being tested?
The study tests the effectiveness of Lacosamide (LCM), given intravenously or orally, against a standard care comparator in reducing neonatal seizure burden as measured by EEG in newborns whose seizures persist after initial treatments.See study design
What are the potential side effects?
While specific side effects for neonates aren't listed here, Lacosamide in older patients can cause dizziness, headache, nausea, and double vision. Side effects may vary based on individual responses.

LENS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I weigh at least 2.3 kg.
Select...
I have taken phenobarbital, levetiracetam, or midazolam before.
Select...
My baby is between 34 and 46 weeks old in corrected gestational age and less than 28 days old since birth.
Select...
My EEG shows I've had significant neonatal seizures.

LENS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during 2-hour evaluation starting 1 hour after initial treatment (up to 2 hours)
This trial's timeline: 3 weeks for screening, Varies for treatment, and during 2-hour evaluation starting 1 hour after initial treatment (up to 2 hours) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in seizure burden measured in the Evaluation video-electroencephalogram (video-EEG) compared with the Baseline video-EEG
Secondary outcome measures
Categorized percentage change in seizure burden in the Evaluation video-EEG compared with the Baseline video-EEG
Percentage of participants with at least 80% reduction in seizure burden in the Evaluation a video-EEG compared with the Baseline video-EEG
Therapeutic procedure
+5 more

LENS Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: LacosamideExperimental Treatment2 Interventions
Study participants randomized to this arm will receive lacosamide (LCM) as an intravenous infusion in the Treatment Period and may continue to receive lacosamide in the Extension Period. Participants should be switched to oral dosing of LCM as soon as medically possible during the Extension Period.
Group II: Active ComparatorActive Control1 Intervention
Study participants randomized to this arm will receive Active Comparator chosen based on standard of care (StOC) in the Clinical Practice in the Treatment Period and may continue to receive in the Extension Period.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lacosamide oral
2013
Completed Phase 1
~30

Find a Location

Who is running the clinical trial?

UCB Biopharma SRLLead Sponsor
101 Previous Clinical Trials
21,391 Total Patients Enrolled
UCB CaresStudy Director001 844 599 2273
204 Previous Clinical Trials
44,887 Total Patients Enrolled

Media Library

Active Comparator Clinical Trial Eligibility Overview. Trial Name: NCT04519645 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this clinical trial taking place at more than one location within the United States?

"Currently, this trial is being conducted in Valhalla, New york; Rochester, Minnesota; and Orange, California--among 21 other locations."

Answered by AI

How many people are included in this clinical research project?

"In order for this study to proceed, 32 patients who meet the necessary qualifications are required. The sponsor, UCB Biopharma SRL, will be administering the trial from multiple locations, such as Sp0968 107 in Valhalla, New york and Sp0968 125 in Rochester, Minnesota."

Answered by AI

Are there any other ongoing or previous research studies that have included Lacosamide oral?

"As of right now, there are 4 ongoing studies that are researching the oral administration of Lacosamide. 3 of those studies are currently in Phase 3. Although the majority of the trials for Lacosamide oral are based in Jacksonville, Florida, there are a total of 166 locations running trials for this treatment."

Answered by AI

Are new patients being accepted into this trial at this time?

"That is accurate. The listing on clinicaltrials.gov says that the research team is currently looking for 32 individuals to take part in the study at 21 different sites. The trial was first posted on March 31, 2021 and was last updated on October 6, 2022."

Answered by AI
~3 spots leftby Aug 2024